Hydroxychloroquine Sulfate is an antimalarial and disease-modifying antirheumatic drug indicated for malaria, lupus erythematosus and rheumatoid arthritis. We supply it to US manufacturers of tablets.
Data from PubChem (CID 12947) and FDA’s substance registry
CAS number
747-36-4
Molecular formula
C18H28ClN3O5S
Molecular weight
434.0g/mol
FDA UNII
IUPAC name
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol;sulfuric acid
InChIKey
JCBIVZZPXRZKTI-UHFFFAOYSA-N
- Appearance
- White or practically white crystalline powder.
- Solubility
- Freely soluble in water, and practically insoluble in alcohol, chloroform and ether.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
A racemate supplied as the sulfate: 200 mg of the salt is equivalent to 155 mg of base.
On the US market
- Reference product
- PlaquenilNDA 009768
- Approved ANDAs
- 13 with a marketed product
- Approved forms and strengths
- Tablet 100 mg, 200 mg, 300 mg, 400 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com